ETTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 6.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Entasis Therapeutics Insider Trading History Chart

Entasis Therapeutics Share Price & Price History

^$2.19

+0.30 (1.20%)

As of 08/5/2022 01:00 AM ET

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Entasis Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/11/2022	Innoviva, Inc.	Major Shareholder	Buy	7,598,814	$2.20	$16,717,390.80	29,270,476
7/8/2022	Innoviva, Inc.	Major Shareholder	Buy	11,671,662	$2.20	$25,677,656.40	21,671,662

This drone stock is setting up to transform medical supply delivery

From The Tomorrow Investor | Ad

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

SEC Filings (Institutional Ownership Changes) for Entasis Therapeutics (NASDAQ:ETTX)

6.91% of Entasis Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Entasis Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/18/2022	Deltec Asset Management LLC	155,614	$0.34M	0.1%	N/A	0.325%
2/10/2022	Acadian Asset Management LLC	55,813	$0.12M	0.0%	+172.0%	0.117%
11/16/2021	Two Sigma Advisers LP	229,000	$0.77M	0.0%	+40.5%	0.481%
11/16/2021	Two Sigma Investments LP	186,230	$0.62M	0.0%	+13.4%	0.391%
11/15/2021	Alberta Investment Management Corp	65,000	$0.22M	0.0%	-50.0%	0.136%
11/12/2021	Renaissance Technologies LLC	312,545	$1.04M	0.0%	-20.2%	0.656%
11/9/2021	BlackRock Inc.	26,619	$89K	0.0%	-18.8%	0.056%
8/17/2021	Bridgeway Capital Management LLC	110,000	$0.29M	0.0%	-8.3%	0.233%
8/16/2021	Alberta Investment Management Corp	130,000	$0.35M	0.0%	N/A	0.275%
8/16/2021	Occudo Quantitative Strategies LP	23,058	$62K	0.0%	-20.6%	0.049%
8/16/2021	State Street Corp	39,205	$0.11M	0.0%	N/A	0.083%
8/13/2021	Renaissance Technologies LLC	391,629	$1.05M	0.0%	-50.2%	0.828%
8/13/2021	Geode Capital Management LLC	81,121	$0.22M	0.0%	+53.9%	0.171%
8/13/2021	Vanguard Group Inc.	419,997	$1.12M	0.0%	+104.7%	0.888%
8/11/2021	Susquehanna Fundamental Investments LLC	22,094	$59K	0.0%	-47.2%	0.047%
5/21/2021	Citadel Advisors LLC	68,574	$0.15M	0.0%	+26.7%	0.184%
5/19/2021	Squarepoint Ops LLC	91,725	$0.20M	0.0%	+53.8%	0.246%
5/18/2021	Citadel Advisors LLC	68,574	$0.15M	0.0%	+26.7%	0.184%
5/14/2021	Occudo Quantitative Strategies LP	29,031	$62K	0.0%	+101.0%	0.078%
5/13/2021	Renaissance Technologies LLC	786,606	$1.68M	0.0%	+55.3%	2.108%
5/12/2021	Northern Trust Corp	20,874	$45K	0.0%	+77.0%	0.056%
5/12/2021	Geode Capital Management LLC	52,697	$0.11M	0.0%	+99.9%	0.141%
4/27/2021	Janney Montgomery Scott LLC	70,930	$0.15M	0.0%	+13.2%	0.190%
2/24/2021	Virtu Financial LLC	146,128	$0.36M	0.0%	+478.9%	0.412%
2/16/2021	Squarepoint Ops LLC	59,644	$0.15M	0.0%	N/A	0.168%
2/12/2021	Jaffetilchin Investment Partners LLC	11,000	$27K	0.0%	N/A	0.031%
2/10/2021	Renaissance Technologies LLC	506,389	$1.25M	0.0%	+110.3%	1.427%
2/9/2021	Pivotal bioVenture Partners Investment Advisor LLC	1,180,178	$2.92M	1.0%	N/A	3.327%
1/25/2021	Janney Montgomery Scott LLC	62,663	$0.16M	0.0%	+20.0%	0.177%
12/11/2020	Virtu Financial LLC	25,241	$51K	0.0%	N/A	0.071%
11/17/2020	Paloma Partners Management Co	18,891	$39K	0.0%	N/A	0.053%
11/17/2020	Jane Street Group LLC	20,820	$42K	0.0%	N/A	0.059%

Data available starting January 2016

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Today's Range

Now: $2.19

$2.19

50 Day Range

MA: $2.19

$2.18

$2.20

52 Week Range

Now: $2.19

$1.40

$3.88

Volume

800 shs

Average Volume

239,104 shs

Market Capitalization

$104.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

AI Crypto Tool Could Send One Coin SOARING…

From Crypto 101 Media | Ad

The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project

Discover our #1 crypto pick before it's too late.